)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Novacyt
Novacyt (ALNOV) investor relations material
Novacyt H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Statutory revenue for H1 2026 rose 18% year-over-year to £11.6m, with underlying organic growth of 9% excluding Southern Cross Diagnostics (SCD) sales.
SCD acquisition in March 2026 contributed £1.8m in revenue, expanding presence in Australia and Asia-Pacific.
Instrumentation and Clinical segments delivered strong growth, with 30% and over 20% revenue increases, respectively.
Launched IVDR-certified Yourgene Insight DPYD assay, expanding clinical genetics portfolio in Europe.
Signed a five-year Master Collaboration Agreement with Illumina, with initial projects underway and key staff retained.
Financial highlights
Revenue increased to £11.6m from £9.8m in H1 2025; instrumentation up 30% YoY, clinical up over 20% YoY.
Gross margin declined to 56% from 66% due to SCD's lower distributor margin and stock uplift adjustment.
Adjusted EBITDA loss improved to £3.6m, a year-on-year reduction of over 10%.
Operating loss reduced to £5.1m from £7.1m year-over-year, aided by lower depreciation, amortization, and exceptional charges.
Cash position at 30 June 2026 was £8.9m, down from £19.1m at year-end 2025, with the group remaining debt free.
Outlook and guidance
Majority of cost savings from restructuring expected to be realized in FY2027, with annual savings of £3.2m–£3.4m.
Continued focus on launching new products, expanding customer base, and leveraging the Illumina partnership for future growth.
Board confident in maintaining a gross margin above 60% in the long term and in long-term strategy execution.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Novacyt
- H1 2024 revenue surged to £10.3m, led by Reproductive Health and NIPT growth, with cost synergies on track.ALNOV
Q2 2024 TU - H1 2025 revenue reached £9.8M, with clinical growth and a strong cash position supporting profitability.ALNOVQ2 2025 TU
- Revenue up 18% year-over-year to £11.6 million, driven by organic growth and SCD integration.ALNOVH1 2026 TU
- FY 2025 revenue rose to £20.0m, EBITDA loss narrowed, and APAC growth accelerated.ALNOVH2 2025
- Acquisition delivers immediate profitability, expanded portfolio, and direct market access.ALNOVStatus update
- Revenue up 4% to £20.0m in 2025, with strong cash and growth in Instrumentation and APAC.ALNOVH2 2025 TU
- EBITDA loss narrowed to £4.1m on £9.8m revenue, with strong growth in reproductive health.ALNOVH1 2025
- Revenue up 209% to £10.3m, net loss widened on DHSC costs, cash remains strong.ALNOVH1 2024
- Revenue up 85% to £19.6m, with strong cash and new launches planned for 2025.ALNOVH2 2024
Next Novacyt earnings date
H2 202629 Apr, 2027
Novacyt
Next Novacyt earnings date
H2 202629 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Novacyt S.A. is a biotechnology company focused on the development, manufacturing, and commercialization of clinical diagnostic products. It operates primarily through its business units, including Primerdesign, Lab21 Products, and IT-IS International. The company specializes in in vitro and molecular diagnostics, offering a wide range of assays, reagents, and PCR devices for detecting various infectious diseases, including pathogens responsible for respiratory, gastrointestinal, and insect-borne illnesses. Novacyt serves a global market, providing its products to public hospitals, central laboratories, and private testing facilities. The company is headquartered in Camberley, United Kingdom, and its shares are listed on the Euronext Growth.